Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study-Reference-Cited by-同舟云学术

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Published:2019-10-16 Issue:2 Volume:26 Page:354-363
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Hui Rina,Pearson Alex^ORCID,Cortes Javier^ORCID,Campbell Christine^ORCID,Poirot Camille,Azim Hatem A.,Fumagalli Debora^ORCID,Lambertini Matteo^ORCID,Daly Fergus,Arahmani Amal,Perez-Garcia José,Aftimos Philippe,Bedard Philippe L.^ORCID,Xuereb Laura,Scheepers Elsemieke D.,Vicente Malou^ORCID,Goulioti Theodora,Loibl Sibylle,Loi Sherene^ORCID,Pierrat Marie-Jeanne,Turner Nicholas C.,Andre Fabrice,Curigliano Giuseppe^ORCID

Funder

Institut de Recherches Internationales Servier

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers;International Journal of Molecular Sciences;2024-01-10

2. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer;Scientific Reports;2023-11-18

3. FGFR families: biological functions and therapeutic interventions in tumors;MedComm;2023-09-23

4. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer;npj Breast Cancer;2023-09-08

5. Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling;Cancers;2023-09-04